跳至主要内容
ProhibitedBinding ruleKRNo English translation已检查官方来源导入

타크로리무스(tacrolimus), 그 염류 및유도체

Listed by the Korean MFDS as a substance that may not be used in cosmetics.

监管决定及完整条件

状态
Prohibited
法律地位
Binding rule
监管摘要
Listed by the Korean MFDS as a substance that may not be used in cosmetics.
条件与限制

타크로리무스

物质身份

官方来源名称
타크로리무스(tacrolimus), 그 염류 및유도체
CAS
104987-11-3
EC
Not supplied in this source row
身份映射
standalone:official_korean_name

该身份的跨市场概览

本站目前已有的精确关联记录。某市场缺失表示没有已导入的精确匹配,并不表示准许使用该物质。

1 个市场数据集

South Korea

当前记录
Prohibited

1 条关联记录 · 1 条含特定条件

打开支持记录
CAS 104987-11-3 的 PubChem 二维化学结构
CAS 104987-11-3PubChem CID 445643

CAS 104987-11-3 的已核实化学信息

Tacrolimus

Tacrolimus is a calcineurin inhibitor and potent immunosuppressive agent used largely as a means of prophylaxis against cellular rejection after transplantation. Tacrolimus therapy can be associated with mild serum enzyme elevations, and it has been linked to rare instances of clinically apparent cholestatic liver injury. — LiverTox

IUPAC 名称
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
分子式
C44H69NO12
分子量
804.0 g/mol
精确质量
803.48197664 Da
单同位素质量
803.48197664 Da
XLogP3
2.7
拓扑极性表面积
178.0 Ų
分子复杂度
1480.0
形式电荷
0
氢键供体
3
氢键受体
12
可旋转键
7
重原子
57
共价单元
1

向 PubChem 报告的名称和同义词

FujimycinPrografTsukubaenolideAdvagrafModigrafProtopicTacrolimus anhydrousFK506
另有 16 个已报告名称
FK 506ProtopyAnhydrous TacrolimusTACROLIMUS MONOHYDRATEEnvarsusAvagrafFR-900506PrograftTacrolimus, anhydrousAstagraf XLEnvarsus XRTacrolimus (anhydrous)AdoportCapexionHecoriaPerixis
外部数据库标识符
高级结构统计
已定义的原子立体中心
14
未定义的原子立体中心
0
已定义的键立体中心
2
未定义的键立体中心
0
三维构象异构体
0
机器可读的结构标识符
SMILES
C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
InChI
InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
InChIKey
QJJXYPPXXYFBGM-LFZNUXCKSA-N

来自其他科学数据库的证据

EMBL-EBI ChEBI
标识符精确匹配CHEBI:61049

tacrolimus (anhydrous)

A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.

配方
C44H69NO12
平均质量
804.031 g/mol
单同位素质量
803.48198 Da
形式电荷
0
  • macrolide lactam — is a (CHEBI:145565)
  • bacterial metabolite — has role (CHEBI:76969)
  • immunosuppressive agent — has role (CHEBI:35705)
  • bacterial metabolite — has role (CHEBI:76969)
  • immunosuppressive agent — has role (CHEBI:35705)
  • macrolide lactam — is a (CHEBI:145565)
其他整理的名称
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadec8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN(-)-FK 506FK 506FK506tacrolimusTacrolimustacrolimus anhydrous
来自此来源的交叉引用
  • CAS: 104987-11-3 — KEGG COMPOUND
  • CAS: 104987-11-3 — ChemIDplus
  • CAS: 104987-11-3 — KEGG DRUG
  • REGISTRY_NUMBER: 3647477 — Reaxys
  • REGISTRY_NUMBER: 8821611 — Reaxys
  • MANUAL_X_REF: C01375 — KEGG COMPOUND
  • MANUAL_X_REF: D08556 — KEGG DRUG
  • MANUAL_X_REF: DB00864 — DrugBank
  • MANUAL_X_REF: EP184162 — Patent
  • MANUAL_X_REF: FK5 — PDBeChem
  • MANUAL_X_REF: LMPK04000003 — LIPID MAPS
  • MANUAL_X_REF: US5665727 — Patent

映射方: Exact CAS cross-reference in the ChEBI compound record. 来源更新: 2019-12-03. 检索时间: 2026-08-31. 打开来源记录

NIH PubChem PUG-View
标识符精确匹配445643

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17Њ±10%; in adults liver transplant patients is 22Њ±6%; in healthy subjects is 18Њ±5%. The absolute bioavailability in pediatric liver transplant patients was 31Њ±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition. 来源: Toxin and Toxin Target Database (T3DB)
  • Signal: Danger 来源: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (97.6%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (92.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (91.5%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] 来源: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P301+P316, P318, P319, P321, P330, P405, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 82 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (100%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] 来源: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 来源: European Chemicals Agency (ECHA)
  • Signal: Danger 来源: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H301: Toxic if swallowed [Danger Acute toxicity, oral] 来源: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) 来源: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: IDENTIFICATION AND USE: Tacrolimus is white to off-white crystalline powder. It is a calcineurin-inhibitor immunosuppressant available in several preparations. Tacrolimus in both oral capsules and a solution for IV injection is used for prophylaxis of organ rejection in patients receiving liver, kidney or heart transplants. Tacrolimus topical ointment is used as a second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children. HUMAN EXPOSURE AND TOXICITY: While most acute overdosages of tacrolimus at up to 30 times the intended dose have been asymptomatic and all patients recovered with no sequelae, some acute overdosages were followed by adverse reactions including tremors, abnormal renal function, hypertension, and peripheral edema. At therapeutic doses, patients receiving tacrolimus are at increased risk of developing lymphomas and other malignancies, particularly of the skin, as well as an increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. While there a 来源: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: Signs and Symptoms of Overdose; Tacrolimus toxicity commonly presents as acute kidney injury. Close monitoring of serum creatinine, glomerular filtration rate, and urine output is necessary for patients on tacrolimus. Toxicity may also present as adverse effects, including tremors, electrolyte disturbances, and headaches. Monitor for neurotoxicity, nephrotoxicity, and hypertension. Investigations may indicate increased serum creatinine. An electrocardiogram should be obtained to rule out QT prolongation.; Management of Overdose; No specific antidote is currently available for tacrolimus toxicity, and the drug is not removed by hemodialysis. Management focuses on supportive care, including symptom monitoring and management. Consultation with the poison control center is recommended for current guidance and treatment recommendations. 来源: StatPearls
  • Toxicity Summary: The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells. 来源: Toxin and Toxin Target Database (T3DB)
  • Uses: THERAPEUTIC CATEGORY: Immunosupressant; dermatological treatment of atopic eczema 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Immunosuppressive Agents 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg; approx.) in Germany (2009): >25; Use (kg) in USA (2002): 45; Consumption (g per capita; approx.) in Germany (2009): 0.000305; Consumption (g per capita) in the USA (2002): 0.00016; Calculated removal (%): 6 来源: NORMAN Suspect List Exchange
  • Uses: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis. 来源: Toxin and Toxin Target Database (T3DB)

映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录

科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。

其他来源的覆盖范围和匹配状态
来源结果已检查
EMBL-EBI ChEBI精确匹配2026-08-31
NIH PubChem PUG-View精确匹配2026-08-31

已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。

于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

官方来源与出处

已登记来源
South Korea MFDS cosmetic ingredient data
来源参考
화장품 안전기준 등에 관한 규정, 별표 1, record 1-946
来源记录 ID
1-946
来源版本
2026-19
来源语言
Korean
翻译状态
No English translation
生效日期
2026-03-18
来源更新
2026-03-18
快照检查时间
2026-08-30 04:33 UTC
验证方法
MFDS JSON appendices 1–2 parse; 1077 prohibited, 243 restricted
SHA-256
056de35b843a5e31f709073f9e79d5e6e18f7c9164eb537bb099b185a37ef7d8

已登记的数据集备注

数据集覆盖范围
Ingredient identity and separate restriction/regulation data endpoints
权威性说明
Korean source is canonical; English materials alone are not complete enough for certification

本记录在市场数据集中的位置

1320
条当前 South Korea 记录
1077
条标记为 Prohibited 的记录
1320
条来自此来源版本的记录
1252
条带有 CAS 身份的市场记录

状态分布

在 1320 条当前记录中,有 638 条带有条件文本。条件字段为空时,按上述记录类型解释;绝不会被转换为可无限制使用的声明。

South Korea 市场背景

Complete current appendix dataset

覆盖版本: MFDS Notice 2026-19, effective 18 March 2026

All rows in official Appendix 1 (prohibited) and Appendix 2 (restricted) of the Safety Standards for Cosmetics.

核实清单

  1. Match the Korean canonical substance name and identifiers.
  2. Review all Appendix 1 and 2 matches and conditions.
  3. Check functional-cosmetic and positive-list requirements where applicable.
  4. Confirm current MFDS notice, responsible seller and label obligations.

官方市场来源

核实工作流程与记录完整性

在将此结果用于合规决定之前

  1. 确认“타크로리무스(tacrolimus), 그 염류 및유도체”及每个 CAS/EC 标识符所指的物料与您的供应商规格一致。
  2. Match the Korean canonical substance name and identifiers.
  3. Review all Appendix 1 and 2 matches and conditions.
  4. Check functional-cosmetic and positive-list requirements where applicable.
  5. Confirm current MFDS notice, responsible seller and label obligations.
  6. 记录来源版本,并在生产、备案或上市之前重新核查监管机构。

本记录中的可用字段

  • 官方物质名称可用
  • CAS可用
  • EC未提供
  • 单独的条件文本可用
  • 生效日期可用
  • 快照哈希与方法可用

本页回答的问题

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. Korean source wording is canonical and other positive lists/notices may still apply to the formulation.

该记录引用 화장품 안전기준 등에 관한 규정, 별표 1, record 1-946,来源版本 2026-19。 打开官方来源。

不保证。CAS 有助于确定身份,但各辖区可能对同一物质作出不同分类,并可能适用不同的产品范围、限值、警示语和过渡日期。

稳定引用

타크로리무스(tacrolimus), 그 염류 및유도체. 화장품 안전기준 등에 관한 규정, 별표 1, record 1-946. South Korea. Source version 2026-19. CosIng Checker regulatory record: https://cosingchecker.com/zh-hans/regulations/kr/records/1595/

请将监管机构作为法律依据来引用。本页是结构化的证据索引和核实辅助工具,不能替代官方文本或专业法律评估。

South Korea 的解读与局限

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

如何解读法律地位

The cited row forms part of a binding rule or legally incorporated list for this market.

本页证据

  • 记录结果:Prohibited
  • 法律地位:Binding rule
  • 来源版本:2026-19
  • 生效日期:2026-03-18

它不能证明什么

Korean source wording is canonical and other positive lists/notices may still apply to the formulation.

进一步的权威物质研究

这些来源均不能推翻上述市场决定。

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

在来源处研究此身份

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

在来源处研究此身份

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

在来源处研究此身份

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

在来源处研究此身份

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

在来源处研究此身份

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

在来源处研究此身份

US EPA CompTox CTX APIs

导入需要 API 密钥

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

在来源处研究此身份